SLE systemic lupus erythematosus
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients full-filling the ACR criteria for systemic lupus erythematosus
Exclusion criteria
Exclusion criteria: patients with proven other auto-immune disorders Pregnant women malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to study the expression of IL-7, TSLP, CD30L and their receptors in peripheral blood and urine of patients with SLE as compared to healthy controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| To study their correlation with disease activity and immunological parameters. And to assess inflammatory mediators present in serum and urine, and those expressed by T-cells and myeloid cells, to identify biomarkers that reflect disease activity and will help to stratify patients with SLE. The results of the proposed studies may contribute to a future treatment strategy by blockade of some of the investigated inflammatory mediators. Third objective: Leucocytes will also be stored for DNA isolation, which will be used for analyses of polymorphic sites that might be involved in regulation of transcription of the investigated mol | — |
Countries
Netherlands
Outcome results
None listed